These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 8961163)
1. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. Calvo P; Alonso MJ; Vila-Jato JL; Robinson JR J Pharm Pharmacol; 1996 Nov; 48(11):1147-52. PubMed ID: 8961163 [TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. Calvo P; Vila-Jato JL; Alonso MJ J Pharm Sci; 1996 May; 85(5):530-6. PubMed ID: 8742946 [TBL] [Abstract][Full Text] [Related]
3. The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. De Campos AM; Sánchez A; Gref R; Calvo P; Alonso MJ Eur J Pharm Sci; 2003 Sep; 20(1):73-81. PubMed ID: 13678795 [TBL] [Abstract][Full Text] [Related]
4. Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid. Yamaguchi M; Ueda K; Isowaki A; Ohtori A; Takeuchi H; Ohguro N; Tojo K Biol Pharm Bull; 2009 Jul; 32(7):1266-71. PubMed ID: 19571396 [TBL] [Abstract][Full Text] [Related]
5. Chitosan based nanocarriers for indomethacin ocular delivery. Badawi AA; El-Laithy HM; El Qidra RK; El Mofty H; El dally M Arch Pharm Res; 2008 Aug; 31(8):1040-9. PubMed ID: 18787795 [TBL] [Abstract][Full Text] [Related]
6. Ocular pharmacokinetics profile of different indomethacin topical formulations. Bucolo C; Melilli B; Piazza C; Zurria M; Drago F J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and anti-inflammatory activity in rabbits of a novel indomethacin ophthalmic solution. Chetoni P; Panichi L; Burgalassi S; Benelli U; Saettone MF J Ocul Pharmacol Ther; 2000 Aug; 16(4):363-72. PubMed ID: 10977132 [TBL] [Abstract][Full Text] [Related]
8. [Ocular Drug Delivery System-based on Solid Nanoparticles]. Nagai N Yakugaku Zasshi; 2021; 141(1):47-53. PubMed ID: 33390447 [TBL] [Abstract][Full Text] [Related]
9. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability. Liu R; Liu Z; Zhang C; Zhang B J Pharm Sci; 2012 Oct; 101(10):3833-44. PubMed ID: 22767401 [TBL] [Abstract][Full Text] [Related]
10. [Ion-sensitive nanoemulsion-in situ gel system for ophthalmic delivery of flurbiprofen axetil]. Shen JQ; Gan Y; Gan L; Zhu CL; Zhu JB Yao Xue Xue Bao; 2010 Jan; 45(1):120-5. PubMed ID: 21351461 [TBL] [Abstract][Full Text] [Related]
11. Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Klang S; Abdulrazik M; Benita S Pharm Dev Technol; 2000; 5(4):521-32. PubMed ID: 11109251 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of single-unit commercial immediate-and sustained-release capsules compared with multiple-unit polystyrene microparticles dosage forms of indomethacin. Tamilvanan S; Sa B PDA J Pharm Sci Technol; 2008; 62(3):177-90. PubMed ID: 18661867 [TBL] [Abstract][Full Text] [Related]
13. Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits. Madhu C; Rix PJ; Shackleton MJ; Nguyen TG; Tang-Liu DD J Pharm Sci; 1996 Apr; 85(4):415-8. PubMed ID: 8901080 [TBL] [Abstract][Full Text] [Related]
15. [Preparation of diclofenac sodium liposomes and its ocular pharmacokinetics]. Sun KX; Wang AP; Huang LJ; Liang RC; Liu K Yao Xue Xue Bao; 2006 Nov; 41(11):1094-8. PubMed ID: 17262954 [TBL] [Abstract][Full Text] [Related]
16. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. Gan L; Han S; Shen J; Zhu J; Zhu C; Zhang X; Gan Y Int J Pharm; 2010 Aug; 396(1-2):179-87. PubMed ID: 20558263 [TBL] [Abstract][Full Text] [Related]
17. Energy-dependent endocytosis is responsible for drug transcorneal penetration following the instillation of ophthalmic formulations containing indomethacin nanoparticles. Nagai N; Ogata F; Otake H; Nakazawa Y; Kawasaki N Int J Nanomedicine; 2019; 14():1213-1227. PubMed ID: 30863055 [TBL] [Abstract][Full Text] [Related]
18. Formulation of indomethacin eye drops via complexation with cyclodextrins. Halim Mohamed MA; Mahmoud AA Curr Eye Res; 2011 Mar; 36(3):208-16. PubMed ID: 21275515 [TBL] [Abstract][Full Text] [Related]
19. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. Patel N; Nakrani H; Raval M; Sheth N Drug Deliv; 2016 Nov; 23(9):3712-3723. PubMed ID: 27689408 [TBL] [Abstract][Full Text] [Related]
20. Poly n-butylcyanoacrylate (PNBCA) nanocapsules as a carrier for NSAIDs: in vitro release and in vivo skin penetration. Miyazaki S; Takahashi A; Kubo W; Bachynsky J; Löebenberg R J Pharm Pharm Sci; 2003; 6(2):238-45. PubMed ID: 12935436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]